Physician profile
Akash Pandey
NPI 1477955540
$98,938.33
in general payments reported to CMS, 2019-2025
18 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $16.94 · 2021: $117 · 2022: $229 · 2023: $13K · 2024: $33K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $23K · Travel and Lodging: $6,865 · Food and Beverage: $3,925 · Education: $11.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $36,943.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,785.00 |
| Consulting Fee | $22,794.55 |
| Travel and Lodging | $6,865.42 |
| Food and Beverage | $3,925.00 |
| Education | $11.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $42,158.56 | 2024-2025 | Relizorb |
| Ipsen Biopharmaceuticals, INC | $29,453.53 | 2023-2025 | Bylvay |
| Mirum Pharmaceuticals, INC. | $19,386.14 | 2024-2025 | Livmarli |
| Albireo Pharma, INC. | $6,200.29 | 2022-2023 | Bylvay |
| Abbvie INC. | $425.12 | 2020-2025 | |
| Fresenius Kabi USA, LLC | $367.40 | 2022-2024 | Smoflipid |
| Alexion Pharmaceuticals, INC. | $250.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $217.11 | 2023 | |
| Genzyme Corporation | $168.22 | 2023-2025 | |
| Rhythm Pharmaceuticals, INC. | $116.69 | 2023 | |
| Phadia US INC. | $107.01 | 2021-2022 | |
| Soleno Therapeutics, INC. | $28.00 | 2025 | Vykat Xr |
| Travere Therapeutics, INC. | $23.09 | 2023 | Cholbam |
| Celltrion USA INC. | $18.94 | 2025 | Vegzelma |
| Janssen Biotech, INC. | $18.23 | 2024 | Tremfya |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Pandey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.